KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other Accumulated Expenses (2016 - 2025)

Thermo Fisher Scientific's Other Accumulated Expenses history spans 17 years, with the latest figure at $3.3 billion for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 4.06% year-over-year to $3.3 billion, compared with a TTM value of $3.3 billion through Dec 2025, up 4.06%, and an annual FY2025 reading of $3.3 billion, up 4.06% over the prior year.
  • Other Accumulated Expenses for Q4 2025 was $3.3 billion at Thermo Fisher Scientific, up from $3.2 billion in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $3.4 billion in Q3 2024, with the low at $1.9 billion in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $3.0 billion, with a median of $3.0 billion recorded in 2024.
  • Year-over-year, Other Accumulated Expenses soared 58.89% in 2022 and then fell 11.17% in 2023.
  • Tracing TMO's Other Accumulated Expenses over 5 years: stood at $3.0 billion in 2021, then rose by 13.69% to $3.4 billion in 2022, then decreased by 3.22% to $3.2 billion in 2023, then fell by 1.45% to $3.2 billion in 2024, then grew by 4.06% to $3.3 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Other Accumulated Expenses are $3.3 billion (Q4 2025), $3.2 billion (Q3 2025), and $3.2 billion (Q2 2025).